November 16, 2010
The company is paying down debt from its Alcon purchase and looks to be debt-free in four years, the Financial Times said.
Updated July 1, 2010
A whopping 40 million does of the vaccine expires – and another 30 million doses are likely to be unused, federal government says. GSK, Novartis were among the big H1N1 vaccine providers.
Updated April 16, 2010
Letters sent to the three companies concerned claims made for cancer, pain and bladder-control drugs.
Updated February 22, 2010
Morrisville-based firm, which was co-founded by UNC-CH Chancellor Holden Thorp, will work with venture arm of Swiss drug giant in researching potential metal-based enzyme inhibitors.
January 26, 2010
Drug giant reports strong earnings. It also will pay a $185 million fine in case involving the marketing of its epilepsy drug Trileptal.
Novartis' new CEO Joe Jimenez, left, and Chairman Daniel Vasella
January 4, 2010
Swiss drug maker, which recently opened massive vaccine plant in Holly Springs, N.C., will buy out remainder of Alcon that is held by Nestle SA and other minority shareholders.
Updated November 24, 2009
Mammoth 430,000-square-foot facility could be ready to produce a key ingredient for H1N1 vaccine in December, Swiss company says. Plant will be first in U.S. to produce vaccines based on cell cultures.
New Novartis plant.
Updated October 26, 2009
Massive facility will be used for production of H1N1 vaccine. Some 300 people are expected to be hired. Novartis is under contract to produce vaccine for U.S. government.
Novartis' plant in Holly Springs